Table 3 Descriptive analysis of TILs, T CD8+ and T CD4+/FOXP3+ evaluated in 18 metastatic patients (both at primary tumor and at metastasis) and their 18 matched controls by two independent raters
Rater | Characteristic | Group | |||
|---|---|---|---|---|---|
Cases-primary tumor | Cases-metastasis | Controls-primary tumor | |||
1 | TILs (%) | Min-Max | 0–20 | 0–15 | 0–60 |
Median | 5 | 3.8 | 5 | ||
I-III Q | 0.6–5 | 0.6–5 | 5–17.5 | ||
CD8+ (%) | Min-Max | 0–20 | 0–10 | 0–10 | |
Median | 2.5 | 0 | 5 | ||
I-III Q | 0–5 | 0–1.3 | 0–5 | ||
FOXP3+ (%) | Min-Max | 0–5 | 0–5 | 0–10 | |
Median | 0 | 0 | 0 | ||
I-III Q | 0–0.6 | 0–1.9 | 0–5 | ||
2 | TILs (%) | Min-Max | 0–20 | 0–10 | 0–35 |
Median | 5 | 5 | 7.5 | ||
I-III Q | 5–5 | 1.3–5 | 5–10 | ||
CD8+ (%) | Min-Max | 0–10 | 0–10 | 0–15 | |
Median | 0 | 0 | 5 | ||
I-III Q | 0–5 | 0–0.6 | 2.5–6.9 | ||
FOXP3+ (%) | Min-Max | 0–10 | 0–10 | 0–10 | |
Median | 0 | 1.3 | 0 | ||
I-III Q | 0–3.1 | 0–5 | 0–3.8 | ||